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Introduction
We exploited a genetic mouse model of breast cancer in which mammary tumors spontaneously develop with very high predictability and at very predictable times after birth. The model, called the "PyVT mouse", was created by introducing a cancer-causing gene from polyoma virus (PyV) into the genome of the mouse mammary gland. These mice are otherwise normal except that they all get mammary tumors by 60-85 days of age. Our idea was to ask two very straightforward questions:
(1) what happens to the FGF that is naturally found in the mammary gland when these cancers develop? and (2) what happens to these tumors if there is no FGF in the mammary gland? We reasoned that if FGF is involved in the progression of cancers, then the levels may change as cancer develops. We also reasoned that if there was no FGF present then maybe the natural course of cancer development would change. If it did, then the results would point us to a new target for drug discovery: FGF-dependant breast epithelial cells.
Body
The progress is summarized in the SOW table presented below but also highlighted results are presented in the key research accomplishments section. In this funding period, we exploited the genetically modified and backcrossed mouse line, acquire and analyzed data on tumor progression in these genetically modified animals and completed the staining of different markers of tumor growth (FGF/FGFR), angiogenesis (Factor lX) and tumor supproession (Erg4).
Methods.
Mice: Experiments were conducted under the oversight of the Institutional Animal Care and Use Committee of the University of California, San Diego. This project used three strains of mice: (1) wild-type, (2) PyVT mice developing spontaneous mammary tumors, (3) FGF2 deficient mice. Hemizygous PyVT (t/+) males and FGF-/-females were crossed to generate male offspring that are heterozygous for FGF2 and expresses the transgene. PyVT/FGF2+/-males are crossed with female FGF2+/-mice to yield PyVT/FGF2-/-, PyVT/FGF2+/-, and PyVT/FGF2+/+ mice. Genotypes were identified from tail DNA by slot blot analysis using a probe for PyVT and FGF2. Tumor measurements: We followed cohorts of female PyVT/FGF2-/-, PyVT/FGF2+/-, and PyVT/FGF2-/-mice to evaluate mammary tumor onset, incidence, growth and progression. After weaning, body weights of the mice were recorded weekly and the presence of palpable lesions in the mammary glands were determined. Blinded assessments were done with calipers to measure tumor size in two dimensions. Tumor volumes were calculated using a formula of axb2/2 with a being the length and b the length. Following excessive weight loss or the presence of tumors in excess of 20 mm in length, the mice were killed. Tumor volumes at various time points and tumor weights at necropsy were compared between the three groups using ANOVA followed by a Wilcoxon-Rank test. Immunohistochemistry: To further characterize mammary tumor development in the absence of FGF2, we performed histological characterization of primary tumors at the early stages of tumor development. Mouse mammary fat pads (MFP) were obtained following euthanasia, perfused with PBS and then fixed with 4% paraformaldehyde (PFA) in PBS, pH 7.4. At the time of immunohistological (IHC) staining, paraffin sections were first deparaffinized in xylene and in progressively more dilute solutions of ethanol. Following this, sections were incubated with Proteinase K (Millipore Cat # 21627 0.2 mg/ml) for 10 minutes. These sections were then blocked in normal goat serum (ABC Rabbit Kit PK-4002) for 1 hour and incubated with either antiFactorVIII (Biocare) or anti-FGF2, FGFR1, R2, R3 and R4 (Sigma) and Ecrg4 at concentrations of 1:100 to 1:2000 overnight at 4 C. After washing, sections were then incubated with biotin-conjugated secondary antibody for 30 minutes at room temperature. Between each of the following steps, three separate washes were conducted for 3 minutes each. Endogenous peroxidase activity was quenched with 0.3% hydrogen peroxide in distilled water before the sections were treated with Avidin Biotin Complex (ABC) kit (Vectastatin, Burlingame Ca). For visualization, the sections were incubated with diaminobenzidine substrate for 30 minutes. Following washes, the sections were successively counterstained by incubating in, Hematoxylin, 2% acetic acid, bluing reagent, with separate washes between. Sections were then dehydrated in solutions of progressively more concentrated ethanol and xylene. The cover slips were mounted with Vectamount Mounting Solution. Images were taken with an Olympus FXS100-BSW microscope.
Results
With completion of the breeding program we were able to mine the data collected over the funding period and analyzed parameters beyond the initial markers like appearance, FGF and FGR to include measurements like when did the tumors first arise? did they grow differently in the three lines? Were they distributed at the same sites and were the numbers at each site different. Much of the final data is in the paper currently under review (see appendix A3) and was presented at the Era of Hope meeting in 2011 (Appendix A2) where we were fortunate to get significant feedback from attendees who came to our presentation. These analyses are contained in the summary below. 1. First appearance of tumors: As shown in the example below (Figure 1 ), the cohort of tumor appearance in different generations of lines could be summarized in graphical form as we measured the tumors every 3-5 days. We examined all animals that were created but only included females in the final analyses. They were differentiated by cage and the presence of a right (RC), left (LC) or no marker cut (NC) on ear. Animals were also followed until they were sacrificed because of tumor size. Occasionally a male PyVT carrier that was being used for breeding purposes would develop a palpable tumor, but this was only observed in 4 instances (one of these positive mice is presented in the figure 1 cohort). Data collected during mammary development showed that FGF KO mice had delayed onset of tumorigenesis and when all were collated (see appendix) they were presented in both the abstract and submitted paper. WT mice began to have palpable tumors by day 65, and by day 80 all mice in the cohort had tumors. In contrast, while some FGF2 KO mice began to have palpable tumors around the same time frame, most FGF2-KO mice showed a significantly delayed progression of tumorigenesis, with some palpable tumors only appearing around day 110. Similarly, FGF2+ het mice showed an intermediate phenotype and the onset of tumorigenesis was earlier than was seen in FGF2 KO mice, but later than was seen in WT. This was important to note because it provided evidence of a gene dosing effect and a decreased expression, rather than only a complete knockout affecting tumor growth. 
Tumor size:
Other ways of monitoring and comparing tumor growth include measuring onset and tumor mass. Mammary tumors ( Figure 2C ) in FGF2 KO mice were significantly smaller (P<0.05) than those in FGF+ mice (8 vs. 2) . This significant difference in tumor burden indicated that FGF2 KO mouse tumor cells grew more slowly and is supported by observation that FGF+ mice were sacrificed at earlier time points (105 vs 134 days). This data is consistent with the data presented earlier indicating delayed onset tumorigenesis. We also noted however that the slope of tumor size increase appeared greater in the FGFKO then in the FGF+ mice. Where the mean time from tumor detection to mouse sacrifice was 20 days in the FGF+ mice, it was 10 days in the FGFKO. It was not because animals were not as healthy but instead because tumors grow faster. This suggests the possibility that there is a secondary FGF-independent pathway that is selected in these animals and that the growth is more aggressive even though delayed. The distribution of cancer development in different animal cohort is presented here. Each animal was followed to a maximum of 125 days. In panel A we compared the back crossed line of FGF+ and FGF-KO to detect significant differences that were also found in the comparison of the KO vs Het animals. This suggests a gene dosage effect of FGF.
Tumor location:
In the course of monitoring tumor development in the mice lines, we also examined the location of tumors and assigned each animal with sites corresponding to different mammary pads ( Figure 3A whether the lines showed any preponderance for one location or another for onset but predicted that, because gene expression in the mice lines are not specific, there should be no difference at time of sacrifice. Indeed no differences were observed ( Figure 3B ) in location when they are compared between groups. The experiment was confounded by the variable incidence of tumors at each site so that in the cumulative analyses of total mass (see paper in Appendix A3) we pooled all data regardless of the site of tumor growth. We also concluded that, as expected, location was not a significant indicator for tumor development particularly when it was compared to the time of appearance or the size of tumors that grow. Like blood vessel number in the tumors, the size of final tumor (Panel C) was different in experimental groups. 
Tumor number at different sites:
Another approach for data analyses involved monitoring the number of different tumors at any given site using the same criteria as above (A-F in upper, middle and lower; left and right). Where one tumor would often arise, in fact there were instances in which several palpable tumors would arise at the same site. These analyses proved very difficult because of operator variability and mass fusing over time making it difficult to determine whether one tumor was single or multi-component. While we did an initial analysis of tumor numbers in same loci, we abandoned attempts to quantify individual tumors at each site because end-points were not sufficiently reliable. Differences (Figure 2 , Panel C) represent the total tumor mass.
Histological appearance:
There are several ways to evaluate the tumor state and we had to make a significant number of assumptions in their characterization. For example, the first was that the tumors would be comparable regardless of the site from which they were harvested. To avoid variability however we sought to focus on tumors that developed in the upper-right mammary pad. There were also several endpoints that we used over the funding period and that we discussed in previous reports including myeloperoxidase, collagen lV and Ecrg4. We show here the results with Factor Vlll to visualize blood vessels ( Figure 4) . In order to quantitatively determine blood vessel density, 3 representative fields each measuring about 1500 µm by 1000 µm on slides stained during the same experiment were analyzed. Blood vessels, as highlighted by IHC for Factor VIII, and confirmed by their morphology, were counted in samples from normal mice, mice lacking one, and mice lacking both copies of FGF2. Average vessel counts from the three groups (each n=3) were then compared. Error bars represent the standard error of the mean (SEM), which was derived from the quotient of the sample standard deviation and the square root of the number of samples. We also performed histological characterization of primary tumors and of mammary fat pads at various stages in development and these results are available in the appendix. We also evaluated several other markers of mammary tumor progression to determine whether there might be ways to explain the delayed effects of FGF-KO on tumor appearance and progression in the PyVT mice. The marker that we focused on the most was the candidate tumor suppressor gene called Ecrg4 which our preliminary data of the previous year had found was implicated in the development of mammary cancer. The results were mixed and we have been trying to locate better antibodies to confirm the absence of this gene in mammary cancer and potential changes in its expression with changes with FGF. • FGF2 is a pro-tumorigenic growth factor.
Reportable Outcomes
(published or in-press manuscripts, abstracts, presentations, products, patents, grant funding awarded or applied for, and career developments that resulted from this award during the reporting year)
We have presented the findings at the Era of Hope conference in Florida 2012 (see appendix). We have also prepared a first manuscript that we have submitted for publication (se appendix) and are preparing a second describing the unanticipated finding that Ecrg4 is absent in the tumors that arise from these lines (see preliminary results) and suggest that they may be a used as a marker for mammary cancer.
Conclusion
These data all point towards the fact that FGF2 is a growth factor in the mouse mammary gland and not a pro-differentiation factor. The new establish that antagonist drug development could result in the identification of new classes of anti-breast cancer drugs. The fact that tumors arise even in the KO mice strongly point to the multiplicity of factors supporting mammary tumor development. Alternatively, the findings here could also reflect the "transforming" power of the constitutive expression of PyVT in these mice [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] and the fact that its effects cannot be readily overcome.
In these studies, we assessed whether FGF2 inhibits the onset, growth and progression of mammary tumors or acts as a pro-angiogenic factor that accelerates tumorigenesis. Specifically, we characterized the expression of FGF2 and FGFR1 in the normal and transgenic mouse mammary glands, and assessed tumor development and progression in FGF2 KO and identified the differences in mammary gland morphology and tumor vascularization. FGF2 and FGFR1 in normal and PyVT-positive mice localized to the myo-and basal epithelium. The data demonstrate that the loss of FGF2 resulted in decreased angiogenesis and a delay in tumor onset. In FGF2 KO mice mammary tumors, blood vessel density was markedly reduced with the loss of FGF2 resulting in delayed tumor growth as well as tumors that were significantly smaller. Importantly, mice that were heterozygous for FGF2 showed an intermediate phenotype in tumor onset and growth. This evidence of a gene dosing effect implies that the action of FGF2 depends on its level of expression rather than an "all-or-none" model of signal transduction. Despite the delay, all of the mice in the cohort eventually developed tumors, suggesting that FGF2 plays at most an ancillary role in tumorigenesis. The results are consistent with the hypothesis that FGF2 contributes to tumor development and the progression to malignancy.
Previous studies implicated FGF2 as a pleiotropic [21] but locally acting cytokine that has distinct juxtacrine roles at the interface been various cell types [15, [22] [23] [24] . One of the many established functional roles of endogenous FGF2 is angiogenesis [25] , but it is always exogenous FGF2 that has been shown to stimulate endothelial proliferation and tube formation in in vitro and in vivo models [26, 27] . The role of FGF2 in cancer angiogenesis has been assumed based on its production by most cancer cell lines [28, 29] . However, it is important to note that when breast cancer cell lines are evaluated in vitro or in xenograft models to investigate tumor-stroma interactions, the results are often not applicable to in vivo tumorigenesis due to differences in the composition of the local extracellular matrix[30-33] and the absence of various tissue specific stromal interactions [34] [35] [36] . Furthermore, tumor cells lines are derived from cells at very late stages of tumor progression and selected for growth in cell culture over many passages [37] . At the same time, naturally occurring tumors are rare and unpredictable. In order to overcome these difficulties, we used the MMTV-PyVT mouse model. This model has a high frequency of tumor development [5] , where the PyVT is under control of the mouse mammary tumor virus long terminal repeat promoter (MMTV-LTR) [6] . This model has been shown to be an accurate representation of the development of human breast cancer [3, 4] . The studies described here provide the in vivo demonstration that loss of FGF2 confers a less malignant phenotype due to reduced vascularization. Furthermore, FGF2 and its receptors have been shown to be highly expressed in many breast cancers [38] and has been shown to have direct mitogenic effects in the mammary epithelium as well as activation of migration [17] . Studies have demonstrated a close interaction between hypoxia and heparin sulfate proteoglycans that modulate the levels of FGF2 signaling [39] . However, previous studies described FGF2 as an upstream mediator of angiogenesis [40] that effects further inflammatory responses that are necessary to complete the process of neo-vascularization [18] . In light of these data as well as the findings presented here, we propose that the action of FGF2-while important in initiating angiogenesis in response to hypoxia-induced stress common in the tumor microenvironment as well as direct mitogenic effects through inhibition of p53, upregulation of survivin [41] , and induction of mdm2 [42]-may be superceded by other inflammatory mediators following sufficient inflammatory signaling when it is lost. This hypothesis may harbor significant implications for future therapeutics that attempt to target the action of FGF2. Rather than solely targeting the action of FGF2 on mammary epithelium, there will need to be a combination of therapeutics that will prevent bypassing of FGF2-induced angiogenesis.
There are a variety of clinical studies that have shown that low serum levels of FGF2 correlate with a more malignant phenotype [13] , larger tumor size, later disease stage [14] , and worse overall and disease-free survival [13, 14] . In addition, many pre-clinical studies have also shown that overexpression of FGF2 inhibits growth [43] , although the exact pathway has yet to be elucidated [44] . In contrast, our study shows that the loss of one or both copies of FGF2 results in smaller tumors. Further studies are needed to reconcile this incongruity.
The primary goal of this study was to analyze the contribution of FGF2 to tumor development and progression to malignancy in vivo through gene knockout. Because FGF2 KO mice were shown to have delayed tumor development and growth compared to PyVT controls with endogenous levels of FGF2, we suggest that FGF2 promotes tumor angiogenesis and progression to malignancy. This experiment has validated the concept that FGF2 blockade in the context of breast cancer will be a beneficial therapeutic intervention. The data obtained here demonstrate that the PyVT mammary tumors are sensitive to FGF2 signaling and would identify the PyVT model as an important preclinical model to evaluate therapies aiming to remove FGF2 function. Our results support the conventional view that, presumably because of its powerful mitogenic activity, FGF2 is a pro-tumorigenic growth factor. Although basic fibroblast growth factor (FGF2) was the first pro-angiogenic molecule to be discovered, it has numerous other activities on the growth and differentiation of nonvascular cell types that are both stimulatory and inhibitory, depending on the cell type evaluated, the experimental design used and the context in which it is tested. To this end, we investigated the effects of manipulating endogenous FGF2 on the development of mammary cancer to determine whether its endogenous contribution in vivo was proor anti-tumorigenic. Spontaneous mammary tumor progression in the transgenic MMTV-PyVT mouse model (PyVt +/+ ) is a multi-step process that involves all of the cell targets of FGF2 and its presumed roles in angiogenesis and myoepithelium differentiation. Whereas, the myoepithelium is a natural endogenous source of FGF2 in mammary tissue, we hypothesized that an absence of FGF2 might affect the onset and progression of mammary tumor development in PyVT + mice. When the onset mammary tumor development and progression curves were compared between FGF-het and FGF-KO mice, there was a small but difference suggesting a gene dosing effect. Initial histological analyses of the tumors in each group suggest that, once progression was initiated, there were few differences in tumor histology.
The significant delay in tumor onset in the FGF2-KO mice vs. FGF2-WT mice is consistent with a functionally permissive role for FGF2 in the kinetics of mammary tumor onset and, while they argue against a central role for FGF2 in mammary cancer progression, they suggest that the function of endogenous myoepithelial-derived FGF2 in the mammary gland is growth stimulatory, rather then differentiation stimulatory. To characterize the role of FGF2 in normal and tumor-bearing mammary tissue, immunohistochemical staining was performed to determine the presence and localization of FGF2 in breast tumor ductal epithelium (also summarized in appendix). Diffuse staining for FGF2 was present throughout the myo-and basal ductal epithelium of normal (non-PyVT+) ( Figure 4A ,B) and transgenic PyVT mammary tumors ( Figure 4C ,D) but absent in FGF2 KO ( Figure  4E ,F) mice. The similar staining pattern seen in normal and transgenic PyVT tumors indicated that the introduction of the PyVT oncogene had a limited effect on the expression and localization of endogenous FGF2. In FGF KO tumors, the diffuse staining pattern described earlier was absent, confirming loss of FGF2 immunoreactivity in the knockout.
